The aim of the sub-study of the MYSTAR randomised trial was to analyse the changes in myocardial perfusion in NOGA-defined regions of interest (ROI) with intramyocardial injections of autologous bone marrow mononuclear cells (BM-MNC) using an elaborated transformation algorithm. Patients with recent first acute myocardial infarction (AMI) and left ventricular (LV) ejection fraction (EF) between 30-45% received BM-MNC by intramyocardial followed by intracoronary injection 68 +/- 34 days post-AMI (pooled data of MYSTAR). NOGA-guided endocardial mapping and 99m-Sestamibi-SPECT (single photon emission computer tomography) were performed at baseline and at three months follow-up (FUP). ROI was delineated as a best polygon by connecting of injection points of NOGA polar maps. ROIs were projected onto baseline and FUP polar maps of SPECT calculating the perfusion severity of ROI. Infarct size was decreased (from 27.2 +/- 10.7% to 24.1 +/- 11.5%, p<0.001), and global EF increased (from 38 +/- 6.1% to 41.5 +/- 8.4%, p<0.001) three months after BM-MNC delivery. Analysis of ROI resulted in a significant increase in unipolar voltage (index of myocardial viability) (from 7.9 +/- 3.0 mV to 9.9 +/- 2.7 mV at FUP, p<0.001) and local linear shortening (index of local wall motion disturbances) (from 11.0 +/- 3.9% to 12.7 +/- 3.4%, p=0.01). NOGA-guided analysis of the intramyocardially treated area revealed a significantly increased tracer uptake both at rest (from 56.7 +/- 16.1% to 62.9 +/- 14.2%, p=0.003) and at stress (from 59.3 +/- 14.2% to 62.3 +/- 14.9%, p=0.01). Patients exhibiting >or=5% improvement in perfusion defect severity received a significantly higher number of intramyocardial BM-MNC. In conclusion, combined cardiac BM-MNC delivery induces significant improvement in myocardial viability and perfusion in the intramyocardially injected area.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1160/TH09-08-0520 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Rotator Cuff Repair in Rabbit Osteoporosis With Chitosan Quaternary Ammonium Salt-Coated Nickel-Titanium Memory Alloy Anchors.
Am J Sports Med
January 2025
Department of Orthopaedics, Lanzhou University Second Hospital, Lanzhou, Gansu, P.R. China.
Background: For patients with osteoporosis and rotator cuff tears, there is still no consensus on current treatment methods. The material, structure, and number of anchors have important effects on the repair outcome.
Purpose: To investigate the use of chitosan quaternary ammonium salt-coated nickel-titanium memory alloy (NTMA) anchors to treat rotator cuff injury in shoulders with osteoporosis in a rabbit osteoporosis model.
Donor MHC-specific thymus vaccination allows for immunocompatible allotransplantation.
Cell Res
January 2025
Translational Medical Center for Stem Cell Therapy, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Organ transplantation is the last-resort option to treat organ failure. However, less than 10% of patients benefit from this only option due to lack of major histocompatibility complex (MHC)-matched donor organs and 25%-80% of donated organs could not find MHC-matched recipients. T cell allorecognition is the principal mechanism for allogeneic graft rejection.
View Article and Find Full Text PDFImpact of regenerative procedure on the healing process following surgical root canal treatment: A systematic review and meta-analysis.
PLoS One
January 2025
Key Laboratory of Shaanxi Province for Craniofacial Precision Medicine Research, College of Stomatology, Xi'an Jiaotong University, Xi'an, Chin.
Introduction: Different Guided Tissue Regeneration (GTR) procedures, such as membranes, bone substitute materials, and Autologous Platelet Concentrates (APCs), have been applied after surgical root canal treatment (SRCT), which produce different outcomes. This study aimed to evaluate the impact of regenerative procedures on the healing process following SRCT.
Methods: A comprehensive search of PubMed, Embase, Scopus, Cochrane, and the Web of Science found Randomized Controlled Trials (RCTs) published until February 25, 2024.
Clinical state and future directions of stem cell therapy in stroke rehabilitation.
Exp Neurol
December 2024
Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA; Stanford Stroke Center, Stanford University School of Medicine, Stanford, CA, USA. Electronic address:
Despite substantial advances in the acute management of stroke, it remains a leading cause of adult disability and mortality worldwide. Currently, the reperfusion modalities thrombolysis and thrombectomy benefit only a fraction of patients in the hyperacute phase of ischemic stroke. Thus, with the exception of vagal nerve stimulation combined with intensive physical therapy, there are no approved neuroprotective/neurorestorative therapies for stroke survivors.
View Article and Find Full Text PDFIn vivo tracking of ex vivo generated Zr-oxine labeled plasma cells by PET in a non-human primate model.
Mol Ther
December 2024
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Article Synopsis
- B cells can be engineered to produce therapies for genetic disorders, metabolic diseases, and cancer.
- A method was developed to collect, expand, differentiate, and track B cells from non-human primates (NHPs) using radioactively labeled imaging techniques.
- The study showed that infused B cells successfully targeted the bone marrow, spleen, and liver without serious side effects, indicating the potential for repeated treatments and the viability of NHPs as a model for human B cell medicine research.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!